Show simple item record

dc.contributor.authorMcVeigh, TPen_US
dc.contributor.authorWiggins, Jen_US
dc.contributor.authorWard, Sen_US
dc.contributor.authorKemp, Zen_US
dc.contributor.authorGeorge, AJen_US
dc.coverage.spatialUnited Statesen_US
dc.date.accessioned2018-02-20T11:24:24Z
dc.date.issued2018-08en_US
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/29191429en_US
dc.identifierS1526-8209(17)30489-5en_US
dc.identifier.citationClin Breast Cancer, 2018, 18 (4), pp. 282 - 288en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1376
dc.identifier.eissn1938-0666en_US
dc.identifier.doi10.1016/j.clbc.2017.10.015en_US
dc.description.abstractBACKGROUND: Since April 2013, the UK's National Health Service Breast Screening Programme (NHSBSP) centers have been obliged to provide services for women at the highest risk of breast cancer, including those carrying highly penetrant single gene mutations (BRCA1, BRCA2, TP53). Since then, such individuals previously undergoing surveillance in the Royal Marsden Hospital were referred to their local NHSBSP centers. We aimed to assess patient experience of surveillance provided by local NHSBSP services at 1 and 3 years after repatriation. PATIENTS AND METHODS: High-risk gene mutation carriers referred to the NHSBSP for breast cancer surveillance were identified from a departmental database in the Cancer Genetics Unit and invited to complete questionnaires about their experience of surveillance under this new pathway, first in 2014 and again in 2016. RESULTS: Three hundred forty-six individuals were invited to participate in 2014, of whom 182 responded (53%). A total of 464 patients were invited in 2016, of whom 246 (53%) completed the second questionnaire. Ninety-four percent of patients with residual breast tissue received some screening at the first (n = 161) and second (n = 185) time points. Ninety-one percent of patients (n = 146) received at least recommended surveillance in the year preceding the initial survey, a proportion decreasing slightly by the second time point (n = 164, 87%). Seventeen percent of individuals required additional diagnostic investigations, with cancers detected in 2%. These proportions remained stable between surveys. CONCLUSION: Repatriation of high-risk individuals from Royal Marsden Hospital to NHSBSP centers has been successfully accomplished. Most individuals received appropriate recommended annual surveillance. Further improvements are required to ensure equal and timely provision of recommended surveillance.en_US
dc.format.extent282 - 288en_US
dc.languageengen_US
dc.language.isoengen_US
dc.subjectBRCAen_US
dc.subjectMRIen_US
dc.subjectMammogramen_US
dc.subjectTP53en_US
dc.subjectAdulten_US
dc.subjectAgeden_US
dc.subjectBRCA1 Proteinen_US
dc.subjectBRCA2 Proteinen_US
dc.subjectBreast Neoplasmsen_US
dc.subjectEarly Detection of Canceren_US
dc.subjectFemaleen_US
dc.subjectGenetic Predisposition to Diseaseen_US
dc.subjectHealth Care Surveysen_US
dc.subjectHeterozygoteen_US
dc.subjectHumansen_US
dc.subjectMiddle Ageden_US
dc.subjectMutationen_US
dc.subjectNational Health Programsen_US
dc.subjectTumor Suppressor Protein p53en_US
dc.subjectUnited Kingdomen_US
dc.titleSuccessful Repatriation of Breast Cancer Surveillance for High-Risk Women to the UK National Health Service Breast Screening Programme.en_US
dc.typeJournal Article
dcterms.dateAccepted2017-10-18en_US
rioxxterms.versionofrecord10.1016/j.clbc.2017.10.015en_US
rioxxterms.licenseref.startdate2018-08en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfClin Breast Canceren_US
pubs.issue4en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.volume18en_US
pubs.embargo.termsNot knownen_US
dc.contributor.icrauthorMarsden,en_US
dc.contributor.icrauthorMcVeigh, Terrien_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record